Eyenovia, Inc. (NASDAQ:EYEN) was the recipient of a large drop in short interest in April. As of April 15th, there was short interest totalling 124,600 shares, a drop of 18.9% from the March 31st total of 153,700 shares. Based on an average trading volume of 129,600 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.8% of the shares of the stock are short sold.
Eyenovia stock traded down $0.25 during midday trading on Tuesday, hitting $4.85. 81,648 shares of the stock were exchanged, compared to its average volume of 144,692. The company has a fifty day simple moving average of $5.55 and a two-hundred day simple moving average of $5.26. Eyenovia has a 52 week low of $2.55 and a 52 week high of $7.72. The stock has a market capitalization of $124.28 million, a PE ratio of -4.49 and a beta of 2.27. The company has a quick ratio of 3.77, a current ratio of 3.77 and a debt-to-equity ratio of 0.02.
Eyenovia (NASDAQ:EYEN) last released its quarterly earnings data on Wednesday, March 24th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. As a group, equities research analysts anticipate that Eyenovia will post -0.99 EPS for the current fiscal year.
Several equities research analysts have recently commented on EYEN shares. Zacks Investment Research cut shares of Eyenovia from a “hold” rating to a “sell” rating in a research report on Tuesday, February 9th. HC Wainwright lifted their price objective on shares of Eyenovia from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, April 1st. Finally, Northland Securities began coverage on shares of Eyenovia in a research note on Monday, March 1st. They set an “outperform” rating and a $10.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Eyenovia has an average rating of “Buy” and a consensus price target of $10.35.
In other Eyenovia news, major shareholder Stuart M. Grant purchased 35,000 shares of the stock in a transaction dated Friday, March 5th. The stock was bought at an average price of $5.50 per share, for a total transaction of $192,500.00. Following the transaction, the insider now directly owns 4,254,748 shares in the company, valued at $23,401,114. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Stuart M. Grant purchased 30,692 shares of the stock in a transaction dated Monday, April 19th. The shares were acquired at an average price of $4.89 per share, with a total value of $150,083.88. Following the transaction, the insider now owns 4,279,748 shares in the company, valued at $20,927,967.72. The disclosure for this purchase can be found here. Company insiders own 23.50% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in EYEN. Virtu Financial LLC bought a new position in Eyenovia in the third quarter valued at approximately $51,000. Golden Green Inc. bought a new position in Eyenovia in the fourth quarter valued at approximately $122,000. Wells Fargo & Company MN lifted its stake in Eyenovia by 16,494.7% in the fourth quarter. Wells Fargo & Company MN now owns 12,612 shares of the company’s stock valued at $77,000 after buying an additional 12,536 shares in the last quarter. Northern Trust Corp lifted its stake in Eyenovia by 17.1% in the fourth quarter. Northern Trust Corp now owns 28,426 shares of the company’s stock valued at $172,000 after buying an additional 4,152 shares in the last quarter. Finally, Valeo Financial Advisors LLC bought a new position in Eyenovia in the first quarter valued at approximately $51,000. 7.22% of the stock is currently owned by hedge funds and other institutional investors.
Eyenovia Company Profile
Eyenovia, Inc, a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet. It focuses on achieving clinical microdosing of next-generation formulations of ophthalmic pharmaceutical agents using its ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments.
Recommended Story: What is a Market Correction?
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.